Press Releases

CohBar Presents Preclinical Data on CB4209/CB4211 Program for NASH at the AASLD Liver Meeting® 2017

Menlo Park, California – October 23, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the presentation of preclinical data on its lead CB4209/CB4211 program for NASH at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place October 20-24, 2017 in Washington DC. NASH (non-alcoholic steatohepatitis) affects as many as 12% of adults in the US and there is currently no approved treatment for the disease. read-more

CohBar Presentation at AASLD Liver Meeting 2017

CB4209 and CB4211 are novel, improved peptide analogs of MOTS-c, a mitochondrially encoded peptide with a potential role in maintaining metabolic homeostasis. Metabolic dysfunction is a common underlying factor in the pathogenesis of many age-related diseases including, non-alcoholic fatty liver disease and steatohepatitis (NAFLD and NASH), obesity, type 2 diabetes, neurodegenerative disease, and cancer. The potential utility of CB4209 and CB4211 for the treatment of NASH, obesity, and type 2 diabetes was evaluated in preclinical models using cultured adipocytes, DIO mice, and the STAM® mouse model of NASH.read-more read-more

CohBar, Inc. Announces Scientific Presentation of CB4209/CB4211 Program for NASH at The AASLD Liver Meeting® 2017

Menlo Park, California – October 4, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U) (“CohBar” or the “Company”) today announced that it will present preclinical data on CB4209/CB4211, its lead drug candidate program for nonalcoholic steatohepatitis (NASH) and obesity, at The Liver Meeting® 2017, the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held October 20-24, 2017, in Washington, D.C. Details of the poster presentation will be announced on October 23rd during the presentation. read-more

CohBar to Present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York on September 12, 2017

Menlo Park, California – September 8, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that CohBar’s CEO Simon Allen will be presenting an overview of the Company and its clinical development program at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City on Tuesday, September 12, 2017. read-more

CohBar, Inc. Completes US$5.2 Million Private Placement

Menlo Park, California – July 17, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U) ("CohBar" or the "Company"), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has closed its previously-announced non-brokered private placement offering (the "Offering"). read-more

CohBar, Inc. Announces Private Placement Offering

Menlo Park, California – June 23, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U) (“CohBar” or the “Company”), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it intends to complete a non-brokered private placement offering (the “Offering”) of up to 3,333,334 units (“Units”) at a price of US$1.50 per unit for gross proceeds of up to US$5,000,000. Each unit will consist of one share of the Company’s common stock and one common stock purchase warrant (each a “Warrant”). Each Warrant will entitle the holder to purchase one share of common stock at a price of US$2.25 per share at any time prior to June 30, 2020. read-more

CohBar, Inc.’s CEO Simon Allen to Present at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York

Menlo Park, California – March 30 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York City. read-more

CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

Menlo Park, California – February 21 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has completed a study to evaluate the potential efficacy of its lead drug candidates, MOTS-c peptide analogs CB4209 and CB4211, in a well-established preclinical model of nonalcoholic steatohepatitis (NASH). With these positive study results, the Company continues to advance its lead drug candidates through IND enabling activities, with plans to initiate human clinical trials in early 2018. read-more

CohBar, Inc.’s CEO Simon Allen to Present at the 2017 BIO CEO & Investor Conference in New York

Menlo Park, California – February 9, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 2017 BIO CEO & Investor Conference in New York City. read-more

CohBar, Inc.’s CEO Simon Allen to Present at the 9th Annual Biotech Showcase in San Francisco

Menlo Park, California – January 10, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the Company will present at the 9th Annual Biotech Showcase Conference in San Francisco on Wednesday, January 11th, 2017 at 2:30pm Pacific Time. CohBar’s Chief Executive Officer, Simon Allen, will discuss the Company’s recent announcements about its clinical development program and its ongoing discovery of new biologically active peptides in the mitochondrial genome. read-more

CohBar, Inc. Continues Exploration of Mitochondrial Genome and Expansion of Its IP Portfolio With Filing of 29 New Provisional Patents

Menlo Park, California – December 6, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the discovery of a number of new biologically active peptides encoded within the mitochondrial genome and the filing of 29 additional related provisional patent applications. The provisional patent applications also cover novel analogs developed by CohBar that are based on the biologically active peptides. During 2016, the Company filed over 50 provisional patents related to its mitochondrial peptide discoveries and novel analogs. read-more

CohBar, Inc.’s CEO Simon Allen to Present at BIO Investor Forum 2016

Menlo Park, California – October 18, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging, today announced that its Chief Executive Officer Simon Allen will present an overview of the company and its recent developments at the 2016 BIO Investor Forum in San Francisco. Mr. Allen will discuss CohBar’s recent announcements regarding the advancement of its preclinical candidates CB4209 and CB4211 into IND-enabling activities and the company’s discovery of new biologically active peptides in the mitochondrial genome. read-more

CohBar, Inc. Announces Discovery of New Peptides in the Mitochondrial Genome Company Expands IP Portfolio with 25 New Provisional Patent Applications

Menlo Park, California – October 13, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging, today announced the discovery of a large number of new biologically active peptides encoded within the genome of the mitochondria, together with the filing of 25 new provisional patent applications. The company is evaluating these peptides as possible additions to its pipeline of MBTs, and expects to file additional patent applications going forward. read-more

CohBar Advances First-in-Class Mitochondria Based Therapeutic to IND-Enabling Activities

Menlo Park, California – September 30, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) for age-related diseases, today announced the selection of two analogs from the company’s MOTS-c program for advancement into IND-enabling activities. The drug candidates, CB4209 and CB4211, have demonstrated significant therapeutic potential in pre-clinical models for the treatment of obesity, with additional confirmatory studies planned to determine therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), and as a potential add-on to other drugs for the treatment of type 2 diabetes. read-more

CohBar, Inc. Announces Preclinical Proof-of-principle Publication for SHLP Mitochondrial-derived Peptides and their Role in Metabolic Regulation and Cell Viability
SHLP Family of Peptide Hormones, Shows Therapeutic Potential for Treating Diseases of Aging

Menlo Park, California - April 11, 2016 - CohBar, Inc. (OTCQX: CWBR and TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced that researchers at the University of Southern California (USC), in collaboration with investigators at the Institute for Aging Research at the Albert Einstein College of Medicine of Yeshiva University (Einstein), have demonstrated the ability of small humanin-like peptides (SHLPs), a novel family of six peptide hormones discovered by the group, to regulate metabolism and cell viability in preclinical studies. The research, “Naturally Occurring Mitochondrial-derived Peptides are Age-dependent Regulators of Apoptosis, Insulin Sensitivity, and Inflammatory Markers,” appears online and in the April 2016 issue of Aging. CohBar has the exclusive license for the development of SHLPs into therapeutics. read-more